BR0211365A - Method and kit for inhibiting or reversing weight gain in a patient receiving antipsychotic medication - Google Patents
Method and kit for inhibiting or reversing weight gain in a patient receiving antipsychotic medicationInfo
- Publication number
- BR0211365A BR0211365A BR0211365-1A BR0211365A BR0211365A BR 0211365 A BR0211365 A BR 0211365A BR 0211365 A BR0211365 A BR 0211365A BR 0211365 A BR0211365 A BR 0211365A
- Authority
- BR
- Brazil
- Prior art keywords
- weight gain
- inhibiting
- kit
- patient receiving
- receptor antagonist
- Prior art date
Links
- 230000004584 weight gain Effects 0.000 title abstract 3
- 235000019786 weight gain Nutrition 0.000 title abstract 3
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 229940124604 anti-psychotic medication Drugs 0.000 title 1
- 229940126013 glucocorticoid receptor antagonist Drugs 0.000 abstract 3
- 239000003850 glucocorticoid receptor antagonist Substances 0.000 abstract 3
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 2
- 230000000561 anti-psychotic effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960000890 hydrocortisone Drugs 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 abstract 1
- 229960003248 mifepristone Drugs 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Abstract
This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents capable of inhibiting the binding of cortisol to its receptors can be used in methods for preventing antipsychotic-induced weight gain. Mifepristone, a potent specific glucocorticoid receptor antagonist, can be used in these methods. The invention also provides a kit for preventing AP-induced weight gain in a human including a glucocorticoid receptor antagonist and instructional material teaching the indications, dosage and schedule of administration of the glucocorticoid receptor antagonist.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30769301P | 2001-07-23 | 2001-07-23 | |
| PCT/US2002/023441 WO2003009853A1 (en) | 2001-07-23 | 2002-07-22 | Methods for preventing antipsychotic-induced weight gain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0211365A true BR0211365A (en) | 2004-09-21 |
Family
ID=23190816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0211365-1A BR0211365A (en) | 2001-07-23 | 2002-07-22 | Method and kit for inhibiting or reversing weight gain in a patient receiving antipsychotic medication |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6680310B2 (en) |
| EP (1) | EP1408981B1 (en) |
| JP (2) | JP2004537563A (en) |
| KR (1) | KR20040028942A (en) |
| CN (2) | CN1547473A (en) |
| AT (1) | ATE406166T1 (en) |
| AU (1) | AU2002319665B2 (en) |
| BR (1) | BR0211365A (en) |
| CA (1) | CA2454339C (en) |
| CY (1) | CY1108562T1 (en) |
| DE (1) | DE60228579D1 (en) |
| DK (1) | DK1408981T3 (en) |
| ES (1) | ES2312598T3 (en) |
| IL (1) | IL159913A0 (en) |
| MX (1) | MXPA04000692A (en) |
| NZ (1) | NZ530724A (en) |
| PT (1) | PT1408981E (en) |
| WO (1) | WO2003009853A1 (en) |
| ZA (1) | ZA200400444B (en) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2314103T3 (en) * | 2001-08-31 | 2009-03-16 | Corcept Therapeutics, Inc. | METHOD FOR INHIBITING COGNITIVE DETERIORATION IN ADULTS WITH DOWN SYNDROME. |
| NZ527142A (en) * | 2003-07-23 | 2006-03-31 | Douglas Pharmaceuticals Ltd | A stable suspension formulation |
| GB0400031D0 (en) | 2004-01-03 | 2004-02-04 | Univ Sheffield | Depression treatment |
| US20050171088A1 (en) * | 2004-01-30 | 2005-08-04 | Astrazeneca Ab | Treatment of psychoses with dibenzothiazepine antipsychotic |
| US20060211667A1 (en) * | 2005-03-21 | 2006-09-21 | Eric Marchewitz | Use of pregnane steroid derivatives for enhancing physical performance |
| US8551986B2 (en) * | 2005-12-08 | 2013-10-08 | The Mclean Hospital Corporation | Treatment of sequelae of psychiatric disorders |
| WO2008128166A1 (en) * | 2007-04-13 | 2008-10-23 | Concert Pharmaceuticals Inc. | Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds |
| US10500216B2 (en) | 2011-11-18 | 2019-12-10 | Corcept Therapeutics, Inc. | Optimizing mifepristone absorption |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| US12226412B2 (en) | 2012-05-25 | 2025-02-18 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| BR112016011826B1 (en) | 2013-11-25 | 2022-09-27 | Corcept Therapeutics, Inc | COMPOUND, PHARMACEUTICAL COMPOSITION AND USE OF SAID COMPOUND |
| US9943526B2 (en) | 2015-04-21 | 2018-04-17 | Corcept Therapeutics, Inc. | Optimizing mifepristone levels for cushing's patients |
| MX2019011543A (en) | 2017-03-31 | 2019-12-16 | Corcept Therapeutics Inc | Glucocorticoid receptor modulators to treat cervical cancer. |
| US11273166B2 (en) | 2017-06-13 | 2022-03-15 | Monash University | Methods and compositions for the treatment of obesity |
| MX2021007322A (en) | 2018-12-19 | 2021-07-07 | Corcept Therapeutics Inc | Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound. |
| WO2020132046A1 (en) | 2018-12-19 | 2020-06-25 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| NZ778399A (en) | 2019-02-22 | 2024-11-29 | Corcept Therapeutics Inc | Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator |
| KR20210153056A (en) * | 2019-03-18 | 2021-12-16 | 리네트 케이. 니만 | How to improve insulin sensitivity |
| EP4072556A4 (en) * | 2019-12-11 | 2024-01-03 | Corcept Therapeutics Incorporated | Methods of treating antipsychotic-induced weight gain with miricorilant |
| US12144812B2 (en) * | 2020-05-06 | 2024-11-19 | Corcept Therapeutics Incorporated | Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators |
| WO2022134033A1 (en) | 2020-12-25 | 2022-06-30 | Corcept Therapeutics Incorporated | Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| AU2023355849A1 (en) | 2022-10-06 | 2025-04-03 | Corcept Therapeutics Incorporated | Formulations of glucocorticoid receptor modulators |
| IL320512A (en) | 2022-10-28 | 2025-06-01 | Corcept Therapeutics Inc | Treatments for amyotrophic lateral sclerosis using dazucorilant |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2757400B1 (en) * | 1996-12-19 | 1999-12-17 | Hoechst Marion Roussel Inc | APPLICATION OF ANTIGLUCOCORTICOIDAL COMPOUNDS IN THE TREATMENT OF PSYCHOSIS OR ADDICTIVE BEHAVIORS |
| US5929058A (en) | 1996-12-24 | 1999-07-27 | Zymogenetics, Inc. | Treatment agents and methods for treating type II diabetes and symptoms of type II diabetes |
| IL135469A0 (en) | 1997-10-06 | 2001-05-20 | Univ Leland Stanford Junior | Methods for treating psychosis associated with glucocorticoid related dysfunction |
| EP1076562B1 (en) | 1998-05-15 | 2006-02-15 | The Board Of Trustees Of The Leland Stanford Junior University | Glucocorticoid receptor antagonists for the treatment of dementia |
| JP2003500353A (en) * | 1999-05-19 | 2003-01-07 | アストラゼネカ・アクチエボラーグ | Treatment method |
-
2002
- 2002-07-22 BR BR0211365-1A patent/BR0211365A/en not_active Application Discontinuation
- 2002-07-22 CN CNA028166647A patent/CN1547473A/en active Pending
- 2002-07-22 KR KR10-2004-7001039A patent/KR20040028942A/en not_active Ceased
- 2002-07-22 WO PCT/US2002/023441 patent/WO2003009853A1/en not_active Ceased
- 2002-07-22 DK DK02750269T patent/DK1408981T3/en active
- 2002-07-22 AU AU2002319665A patent/AU2002319665B2/en not_active Ceased
- 2002-07-22 IL IL15991302A patent/IL159913A0/en not_active IP Right Cessation
- 2002-07-22 PT PT02750269T patent/PT1408981E/en unknown
- 2002-07-22 AT AT02750269T patent/ATE406166T1/en active
- 2002-07-22 MX MXPA04000692A patent/MXPA04000692A/en active IP Right Grant
- 2002-07-22 CN CNA2005101236436A patent/CN1853722A/en active Pending
- 2002-07-22 NZ NZ530724A patent/NZ530724A/en not_active IP Right Cessation
- 2002-07-22 EP EP02750269A patent/EP1408981B1/en not_active Expired - Lifetime
- 2002-07-22 US US10/201,356 patent/US6680310B2/en not_active Expired - Lifetime
- 2002-07-22 ES ES02750269T patent/ES2312598T3/en not_active Expired - Lifetime
- 2002-07-22 CA CA2454339A patent/CA2454339C/en not_active Expired - Fee Related
- 2002-07-22 DE DE60228579T patent/DE60228579D1/en not_active Expired - Lifetime
- 2002-07-22 JP JP2003515245A patent/JP2004537563A/en active Pending
-
2004
- 2004-01-21 ZA ZA2004/00444A patent/ZA200400444B/en unknown
-
2008
- 2008-11-12 CY CY20081101296T patent/CY1108562T1/en unknown
-
2009
- 2009-02-03 JP JP2009023156A patent/JP2009102413A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2454339C (en) | 2012-01-10 |
| AU2002319665B2 (en) | 2006-09-21 |
| DK1408981T3 (en) | 2009-01-12 |
| JP2004537563A (en) | 2004-12-16 |
| HK1061526A1 (en) | 2004-09-24 |
| EP1408981B1 (en) | 2008-08-27 |
| NZ530724A (en) | 2005-09-30 |
| ATE406166T1 (en) | 2008-09-15 |
| CN1853722A (en) | 2006-11-01 |
| KR20040028942A (en) | 2004-04-03 |
| US20030027802A1 (en) | 2003-02-06 |
| ES2312598T3 (en) | 2009-03-01 |
| IL159913A0 (en) | 2004-06-20 |
| PT1408981E (en) | 2008-12-04 |
| ZA200400444B (en) | 2005-03-30 |
| JP2009102413A (en) | 2009-05-14 |
| EP1408981A4 (en) | 2005-06-08 |
| EP1408981A1 (en) | 2004-04-21 |
| CY1108562T1 (en) | 2014-04-09 |
| US6680310B2 (en) | 2004-01-20 |
| CN1547473A (en) | 2004-11-17 |
| CA2454339A1 (en) | 2003-02-06 |
| WO2003009853A1 (en) | 2003-02-06 |
| MXPA04000692A (en) | 2004-04-21 |
| DE60228579D1 (en) | 2008-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0211365A (en) | Method and kit for inhibiting or reversing weight gain in a patient receiving antipsychotic medication | |
| IL139672A0 (en) | Glucocorticoid receptor antagonists for the treatment of dementia | |
| WO2002076390A3 (en) | Methods for treating stress disorders using glucocorticoid receptor-specific antagonists | |
| WO2004058717A8 (en) | Isoquinolinone derivatives and their use as therapeutic agents | |
| AU2003228283A1 (en) | Quinazolinone modulators of nuclear receptors | |
| NO20062504L (en) | Compositions and dosage forms for improved absorption | |
| NO20003534D0 (en) | Progesterone receptor modulator compounds, pharmaceutical compositions containing them and the use of the compounds | |
| ECSP077236A (en) | PROGESTERONE RECEIVER MODULATORS UNDERSTANDING PIRROL-OXINDOL DERIVATIVES AND USES OF THE SAME | |
| ATE498395T1 (en) | GENERAL LINEAR EFFORTABLE FORM OF FENTANYL FOR ORAL USE AND METHOD OF ADMINISTRATION | |
| AR026916A1 (en) | PHARMACEUTICAL COMBINATIONS AND THEIR USE IN THE TREATMENT OF GASTROINTESTINAL DISORDERS | |
| HK1047050A1 (en) | Methods for treating mild cognitive impairment | |
| IL160649A0 (en) | Methods for inhibiting cognitive deterioration in adults with down syndrome | |
| WO2004069202A3 (en) | Antiglucocorticoids for the treatment of postpartum psychosis | |
| MX2007003545A (en) | Compositions and methods for treating cognitive disorders. | |
| IL158744A0 (en) | Methods for treating delirium using glucocorticoid receptor-specific antagonists | |
| DK1165184T3 (en) | Estrogen receptor beta antagonism and bone diseases | |
| AR026756A1 (en) | NEW THERAPEUTIC COMBINATIONS (S) -2-BENCILAMINO-METIL) -2,3,8,9-TETRAHIDRO-7H-1,4-DIOXINO [2,3-E] INDOL-8-ONA AND NEUROLETICS FOR THE OPREVENTION TREATMENT OF PSYCHOTIC DISORDERS | |
| WO2002020526A3 (en) | Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents | |
| ECSP003820A (en) | PHARMACEUTICAL COMBINATIONS AND THEIR USE IN THE TREATMENT OF GASTROINTESTINAL DISORDERS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: PARA INT.CL: A61K 31/56, A61P 25/00 Ipc: A61K 31/56 (2011.01) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |